Effects of the soluble fiber complex PolyGlycopleX® (PGX®) on glycemic control, insulin secretion, and GLP-1 levels in Zucker diabetic rats.
OBJECTIVE
The effects of the novel water soluble, viscous fiber complex PolyGlycopleX® [(α-D-glucurono-α-D-manno-β-D-manno-β-D-gluco), (α-L-gulurono-β-D mannurono), β-D-gluco-β-D-mannan (PGX®)] on body weight, food consumption, glucose, insulin, and glucagon-like peptide (GLP-1) levels were determined in Zucker diabetic rats (ZDFs). Such fibers are thought to improve glycemic control through increased GLP-1 induced insulin secretion.


METHODS
ZDFs were treated 12 weeks with normal rodent chow supplemented with cellulose (control, inert fiber), inulin or PGX® at 5% wt/wt and effects on body weight, glycemic control, and GLP-1 determined.


RESULTS
In the fed state, PGX® reduced blood glucose compared to the other groups from week 5 until study termination while insulin was significantly elevated when measured at week 9, suggesting an insulin secretagogue effect. Fasting blood glucose was similar among groups until 7-8 weeks when levels began to climb with a modest reduction caused by PGX®. An oral glucose tolerance test in fasted animals (week 11) showed no change in insulin sensitivity scores among diets, suggesting an insulinotropic effect for PGX® rather than increased insulin sensitivity. PGX® increased plasma levels of GLP-1, while HbA(1c) was markedly reduced by PGX®. Body weights were not changed despite a significant reduction in food consumption induced by PGX® up to week 8 when the PGX®-treated group showed an increase in body weight despite a continued reduction in food consumption.


CONCLUSIONS
PGX® improved glycemic control and reduced protein glycation, most likely due to the insulin secretagogue effects of increased GLP-1.
Department of Pharmacology, EurofinsUS, Dayton, NJ 08810, United States. garygrover@productsafteylabs.comUS.com
Gary J
GJ
Grover
Lee
L
Koetzner
Joan
J
Wicks
Roland J
RJ
Gahler
Michael R
MR
Lyon
Raylene A
RA
Reimer
Simon
S
Wood
D000464:Alginates / Q000008:administration & dosage*; D000821:Animal Feed; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D001835:Body Weight / Q000187:drug effects; D002482:Cellulose / Q000008:administration & dosage; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D004338:Drug Combinations; D004435:Eating / Q000187:drug effects; D052216:Glucagon-Like Peptide 1 / Q000097:blood*; D005951:Glucose Tolerance Test; D006442:Glycated Hemoglobin / Q000378:metabolism; D006943:Hyperglycemia / Q000097:blood / Q000178:diet therapy*; D007328:Insulin / Q000097:blood*; D008297:Male; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage*; D051381:Rats; D011924:Rats, Zucker
D000464:Alginates; D001786:Blood Glucose; D002482:Cellulose; D004338:Drug Combinations; D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D007328:Insulin; D011135:Polysaccharides, Bacterial; C540519:PolyGlycoplex